Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjects.

•Evolocumab treatment improves postprandial responses of triglyceride-rich lipoproteins in type II diabetics.•Evolocumab treatment decreases remnant lipoproteins as well as small very-low-density lipoprotein and low-density lipoprotein.•This reduces atherosclerotic cardiovascular disease risk as the atherogenic potential of remnants equal that of low-density lipoprotein.•It is important to test postprandial responses when evaluating novel drug therapies.